

BPC-157

Body Protection Compound-157 / Pentadecapeptide (regenerative, cytoprotective)

Schedule: Rx only (compounded)

Route: Subcutaneous / Oral

Dosage Form: Sterile injection, oral capsule

Compounding Standard: USP 797 sterile compounded

1. Medication Identification

15 amino acid pentadecapeptide derived from a protective sequence in gastric juice. PCI
Pharmacy formulations: 2.5 mg/mL sterile injection in 3 mL vials and 500 mcg oral capsules.

2. Indication / Therapeutic Use

Off-label / investigational support for soft tissue repair (tendon, ligament, muscle), GI mucosal integrity (IBS, IBD, leaky gut), post-surgical recovery, and chronic inflammatory pain.

3. Dosing and Administration

Injectable: 250 to 1000 mcg subcutaneous

Oral: 500 to 1000 mcg daily

Timing: Before bed or as directed by prescriber, advised to take away from food to avoid insulin negative feedback on IGF-1 following anticipated increase in growth hormone receptor expression.

Duration: Per prescriber protocol; typically 4 to 8 weeks

What to do if a dose is missed: Administer/Take your next dose when you remember. If within 12 hours of your next scheduled dose, skip the dose and take your next dose as scheduled. Do not double dose to compensate for a missed dose.

4. Mechanism of Action / Pharmacology

Upregulates growth hormone receptor expression at sites of tissue injury, stimulates VEGF-driven angiogenesis, modulates NO-synthase signaling, and preserves intestinal mucosal integrity through cytoprotective pathways.

5. Contraindications

- ☐ Known hypersensitivity to BPC-157 or any excipient
- ☐ Pregnancy or lactation
- ☐ Pediatric use (insufficient data)
- ☐ Active malignancy (theoretical angiogenic concern)

6. Warnings and Precautions

- ☐ Not FDA approved as a finished drug product; investigational compounded preparation
- ☐ Counsel patient on off-label / investigational status
- ☐ Long-term safety data are limited

7. Adverse Reactions

- ☐ Generally very well tolerated
- ☐ Rare mild nausea
- ☐ Transient injection site discomfort
- ☐ Serious adverse reactions uncommon

8. Drug Interactions

- ☐ No clinically significant documented interactions
- ☐ Potential additive effect with other regenerative or anti-inflammatory agents
- ☐ Coordinate with anticoagulants given angiogenic activity

9. Storage, Stability, and Beyond-Use Date

Visually inspect vial to ensure no precipitants, damage or cloudy liquid remains. Visually inspect capsules to verify they are all the same size and color, and fully intact. Injectable: refrigerated at 35 – 42 degrees Fahrenheit, do not freeze, protected from light. Oral capsules: refrigerated at 35 – 42 degrees Fahrenheit, do not freeze, away from heat, light, and moisture. Beyond-use date per pharmacy SOP and USP 797 guidance.

10. Compounding and Dispensing Notes

Prepared under USP 797 sterile conditions. Dispensed as a finished compounded product. Inspect vial for clarity and particulates prior to dispensing. Document lot, BUD, and patient-specific Rx.